Organisation paid for research Program year 2025 Source: CMS Open Payments

Win Retina

Neither a doctor nor a teaching hospital

Research payments

$4,102,336

1,300 payments

Through program year 2025, Win Retina is reported as receiving $4,102,336 in research payments, across 1,300 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,017,865	347
2024	Research	$792,748	884
2023	Research	$375,856	23
2022	Research	$843,109	22
2021	Research	$927,697	16
2020	Research	$132,923	4
2019	Research	$12,137	4

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $3,024,327 1,042 payments
Kyowa Kirin, Inc. $849,977 237 payments
Roche TCRC, Inc. $214,681 16 payments
Allergan Inc. $13,350 5 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $2,525,546 861 payments
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema $666,384 184 payments
A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $498,782 181 payments
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration $183,594 53 payments
Phase 2 Study of Anti Il6 Mab With RBZ in Combination in Patients With Dme $112,241 5 payments
Oral Treatment of NPDR $52,756 7 payments
Phase 2 Study to Investigate Ro7200220 in Diabetic MacUlar Edema $49,684 4 payments
A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related MacUlar Degeneration $10,949 4 payments
Phase 2 - Evaluation of Abicipar Pegol in Patients With Namd 1771-201-008 $2,401 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.